Durvalumab for the Management of Urothelial Carcinoma: A Short Review on the Emerging Data and Therapeutic Potential
A review of durvalumab, an immune checkpoint inhibitor approved for the treatment of urothelial carcinoma.
Diagnosis & Disease Information
Early Checkpoint Inhibition With Cytotoxic Chemotherapy Improves OS, PFS in Extensive-Stage SCLC
In this randomized, double-blind, placebo-controlled study, researchers sought to determine the effect of including a checkpoint inhibitor in induction therapy for patients with extensive-stage small cell lung cancer.
Drug Classification of Trastuzumab
Is trastuzumab classified as an immunotherapy? If so, how does it work?
2-Year Rituximab Maintenance Therapy Prolongs PFS in Elderly With CLL
Investigators sought to determine the efficacy of 2-year rituximab maintenance therapy in elderly patients with CLL who achieve a complete response to abbreviated FCR induction therapy.
Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
The US FDA approved pertuzumab in combination with trastuzumab and chemotherapy for adjuvant treatment of HER2-positive early breast cancer, and converted accelerated to full approval for the regimen as neoadjuvant therapy in certain breast cancers.
Bisphosphonates vs Denosumab: Preventing SREs in Breast Cancer With Bone Metastasis
A comparison study presented at the 2017 SABCS sought to determine the effectiveness of bisphosphonates with denosumab for skeletal-related events in women with breast cancer metastases to bone.
Prolonging Survival in MM: Daratumumab vs Pomalidomide Plus Dexamethasone
A head-to-head comparison investigated whether patients with multiple myeloma achieved greater prolongation in overall survival with daratumumab monotherapy or pomalidomide plus low-dose dexamethasone.
Brentuximab Vedotin Granted FDA Approval for pcALCL, Mycosis Fungoides
The US FDA has granted regular approval to brentuximab vedotin (Adcetris) for pcALCL and CD30-expressing MF in adult patients who received prior systemic therapy.
A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer
In this case, a female patient with advanced lung cancer experiences a rare episode of nivolumab-induced Herzmyasthenie, emphasizing the need to be aware of the potential for rapid myocarditis concomitant with MG in patients undergoing treatment with anti-PD-1 monoclonal antibodies.
Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
Two phase 3 studies reveal the clinical benefit, safety profile, and overall survival of nivolumab and docetaxel for patients with squamous and nonsquamous NSCLC.
- Loading...
Loading...
Next post in Lung Cancer
Loading... 
Loading...